Author
Listed:
- Carlo Efisio Marras
(Neurosurgery Unit, Department of Neuroscience, IRCCS Bambino Gesù Children Hospital, 00165 Rome, Italy)
- Gabriella Colicchio
(Department of Neurosurgery, UCSC Gemelli University Hospital, 00167 Rome, Italy)
- Luca De Palma
(Pediatric Neurology Unit, Department of Neuroscience, IRCCS Bambino Gesù Children Hospital, 00165 Rome, Italy)
- Alessandro De Benedictis
(Neurosurgery Unit, Department of Neuroscience, IRCCS Bambino Gesù Children Hospital, 00165 Rome, Italy)
- Giancarlo Di Gennaro
(Neurology Unit, IRCCS Neuromed Institute, 86077 Pozzilli, Italy)
- Marilou Cavaliere
(Neurosurgery Unit, Department of Neuroscience, IRCCS Bambino Gesù Children Hospital, 00165 Rome, Italy
Institute of Neurosurgery, University of Milan Bicocca, 20900 Milan, Italy)
- Elisabetta Cesaroni
(Pediatric Neurology Unit, Salesi Children Hospital, 60123 Ancona, Italy)
- Alessandro Consales
(Pediatric Neurosurgery Unit, G. Gaslini Hospital, 16147 Genoa, Italy)
- Sofia Asioli
(Department of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology, Bellaria Hospital, University of Bologna, 40139 Bologna, Italy)
- Massimo Caulo
(Department of Neuroscience, Imaging and Clinical Sciences, University of Chieti, 66100 Chieti, Italy)
- Flavio Villani
(Division of Clinical Neurophysiology and Epilepsy Center, IRCCS, San Martino Hospital, 16132 Genoa, Italy)
- Nelia Zamponi
(Pediatric Neurology Unit, Salesi Children Hospital, 60123 Ancona, Italy)
Abstract
Background : Vagus nerve stimulation (VNS) is a palliative treatment for medical intractable epileptic syndromes not eligible for resective surgery. Health technology assessment (HTA) represents a modern approach to the analysis of technologies used for healthcare. The purpose of this study is to assess the clinical, organizational, financial, and economic impact of VNS therapy in drug-resistant epilepsies and to establish the congruity between costs incurred and health service reimbursement. Methods : The present study used an HTA approach. It is based on an extensive detailed bibliographic search on databases (Medline, Pubmed, Embase and Cochrane, sites of scientific societies and institutional sites). The HTA study includes the following issues: (a) social impact and costs of the disease; (b) VNS eligibility and clinical results; (c) quality of life (QoL) after VNS therapy; (d) economic impact and productivity regained after VNS; and (e) costs of VNS. Results: Literature data indicate VNS as an effective treatment with a potential positive impact on social aspects and on quality of life. The diagnosis-related group (DRG) financing, both on national and regional levels, does not cover the cost of the medical device. There was an evident insufficient coverage of the DRG compared to the full cost of implanting the device. Conclusions : VNS is a palliative treatment for reducing seizure frequency and intensity. Despite its economic cost, VNS should improve patients’ quality of life and reduce care needs.
Suggested Citation
Carlo Efisio Marras & Gabriella Colicchio & Luca De Palma & Alessandro De Benedictis & Giancarlo Di Gennaro & Marilou Cavaliere & Elisabetta Cesaroni & Alessandro Consales & Sofia Asioli & Massimo Cau, 2020.
"Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy,"
IJERPH, MDPI, vol. 17(17), pages 1-17, August.
Handle:
RePEc:gam:jijerp:v:17:y:2020:i:17:p:6150-:d:403359
Download full text from publisher
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:17:p:6150-:d:403359. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.